Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
L. Elberdín, Rm Fernández-Torres, S. Paradela, E. Blanco, M. Outeda, I. Martín & E. Fonseca. (2020) Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital. Journal of Dermatological Treatment 31:7, pages 698-701.
Read now
Read now
Therezia Bokor-Billmann & Knut Schäkel. (2019) No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. Journal of Dermatological Treatment 30:3, pages 216-220.
Read now
Read now
Elizabeth Adenubiova, Petr Arenberger, Petra Gkalpakioti, Monika Arenbergerova, Jitka Jircikova, Tomas Dolezal & Spyridon Gkalpakiotis. (2018) Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. Journal of Dermatological Treatment 29:6, pages 579-582.
Read now
Read now
Articles from other publishers (10)
Laida Elberdín, Rosa M. Fernández-Torres, María Mateos, María Outeda, Eva Blanco, María I. Gómez-Besteiro, Isabel Martín-Herranz & Eduardo Fonseca. (2022) Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis. Frontiers in Medicine 9.
Crossref
Crossref
Sabrina Giometto, Silvia Tillati, Laura Baglietto, Nicola De Bortoli, Marta Mosca, Marco Conte, Marco Tuccori, Rosa Gini & Ersilia Lucenteforte. (2022) Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. International Journal of Environmental Research and Public Health 19:11, pages 6799.
Crossref
Crossref
Laida Elberdín, Rosa M. Fernández-Torres, Sabela Paradela, María Mateos, Eva Blanco, Vanesa Balboa-Barreiro, María I. Gómez-Besteiro, Maria Outeda, Isabel Martín-Herranz & Eduardo Fonseca. (2022) Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago. Dermatology and Therapy 12:3, pages 761-770.
Crossref
Crossref
Ting-Shun Wang & Tsen-Fang Tsai. (2019) Biologics switch in psoriasis. Immunotherapy 11:6, pages 531-541.
Crossref
Crossref
Yifan Hu, Zeyu Chen, Yu Gong & Yuling Shi. (2017) A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clinical Drug Investigation 38:3, pages 191-199.
Crossref
Crossref
Antonio Costanzo, Giovanna Malara, Claudio Pelucchi, Francesco Fatiga, Giovanna Barbera, Andrea Franchi & Carlotta Galeone. (2018) Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatology 234:1-2, pages 1-12.
Crossref
Crossref
Paul S. Yamauchi, Robert Bissonnette, Henrique D. Teixeira & Wendell C. Valdecantos. (2016) Systematic review of efficacy of anti?tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti?TNF agent. Journal of the American Academy of Dermatology 75:3, pages 612-618.e6.
Crossref
Crossref
L. Eissing, S.J. Rustenbach, M. Krensel, N. Zander, C. Spehr, M.A. Radtke, L. Naldi & M. Augustin. (2016) Psoriasis registries worldwide: systematic overview on registry publications. Journal of the European Academy of Dermatology and Venereology 30:7, pages 1100-1106.
Crossref
Crossref
Francisco Kerdel & Martin Zaiac. (2015) An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatologic Therapy 28:6, pages 390-403.
Crossref
Crossref
P. Sator, L. Richter, W. Saxinger, M. Vasiljevic & G. Stingl. (2015) Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics. Journal of the European Academy of Dermatology and Venereology 29:9, pages 1742-1749.
Crossref
Crossref